MFT
VIVO

Moisand Fitzgerald Tamayo’s Meridian Bioscience Inc VIVO Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-68
Closed -$2K – 862
2022
Q3 		$2K Buy
+68
New +$2.2K ﹤0.01% 554

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moisand Fitzgerald Tamayo's VIVO Position: Q4 2022 in Review

Moisand Fitzgerald Tamayo sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 68 shares — an estimated $2K sold.

Moisand Fitzgerald Tamayo first reported a position in VIVO in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

  • Moisand Fitzgerald Tamayo reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
  • Moisand Fitzgerald Tamayo sold 68 Meridian Bioscience Inc shares in Q4 2022, an estimated $2K.
  • Moisand Fitzgerald Tamayo first reported a position in Meridian Bioscience Inc in Q3 2022 and held it in 1 quarter.
  • Moisand Fitzgerald Tamayo's Meridian Bioscience Inc position peaked at $2K in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q4 2022, filed 23 Jan 2023.